Aurinia announces positive Phase 1 results for aritinercept; robust Ig reductions support once-monthly dosing

Aurinia Pharmaceuticals Inc.

Single doses of aritinercept (5-300 mg s.c.) well tolerated in 61 healthy subjects; no treatment-related Grade ≥3 AEs or SAEs.
Mean immunoglobin reductions at Day 28: IgA up to 48%, IgM up to 55%, IgG up to 20%.
Injection site reactions in 24% aritinercept vs 13% placebo; all Grade 1.
Company plans to initiate clinical studies in at least two autoimmune diseases in H2 2025.
Pharmacodynamic effects support once-monthly subcutaneous dosing.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.